Alex Gorsky Chairman and Chief Executive Officer Johnson & Johnson “Our third-quarter results demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health. In the face of evolving marketplace dynamics resulting from the effects of COVID-19 and other global trends, we have continued to demonstrate the responsiveness and agility required to meet the needs of our stakeholders, while also successfully investing in a pipeline of innovation and key commercial platforms to drive our future growth. I am incredibly proud of our Company’s transformative growth over the last decade. As I prepare to transition the role of CEO to Joaquin Duato in January, I want to extend my deepest gratitude to our colleagues around the globe who work tirelessly to deliver solutions to address the world’s most urgent and unmet healthcare challenges.” For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson’s earnings release issued on October 19, 2021, available at http://www.investor.jnj.com/sales-earnings.cfm. *Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Non-GAAP measure; excludes the impact of translational currency. Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward- Looking Statements” included in the Johnson & Johnson earnings release issued on October 19, 2021, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. 3rd Quarter 2021 Results 3rd Quarter 2021 Sales Adjusted Diluted Earnings Per Share* $2.60 18.2% Increased  Diluted Earnings Per Share $1.37 3.0% Increased  Worldwide Increased  $23.3B 10.6%* 10.7% Worldwide Increased  Excluding acquisitions/ divestitures on an operational basis Note: values may have been rounded $6.6Medical Devices worldwide reported sales increased 8.0% or 7.0% operationally1 . Primary operational drivers: Worldwide Medical Devices Sales Billion Endocutters Energy Biosurgery Surgical Vision Wound Closure Electrophysiology Contact Lens Billion $13.0 Worldwide Pharmaceutical SalesPharmaceutical worldwide reported sales increased 13.8% or 13.2% operationally1 . Primary operational drivers: Consumer Health worldwide reported sales increased 5.3% or 4.1% operationally1 . Primary operational drivers: $3.7 Worldwide Consumer Health Sales Billion -- 1 of 1 --